Non-melanoma skin cancers (NMSC), comprising squamous cell (SCC) and basal cell carcinomas (BCC), have a significant impact upon the health care system because their overall incidence is higher than for all other cancers combined. Therefore, while not usually fatal, these skin carcinomas incur a very high cost for their management, e.g., 90% of the cost of treating breast cancer. The current standard of care is surgical excision with wide margins. Major morbidity stems from fibrosis, scarring, and loss of function after treatment. Photodynamic therapy (PDT) using 5-aminotevulinicacid (ALA) represents a non-disfiguring alternative to surgery, especially for patients with multiple tumors and for tumors in delicate sites. Currently, the efficacy of ALA-PDT is not adequate to realistically compete with surgery in the U.S.A. Based on one of the Program themes of Combination Photodynamic Biologic Therapy (CPBT), in Project 1, our overall hypothesis is that tumor-differentiating agents can be used to improve the efficacy of ALA-PDT so that PDT becomes a viable alternative to surgery for NMSC. Wewill build upon our discovery that two small molecules, methotrexate (MTX) and vitamin D (Vit D), can increase tumor cell differentiation and at the same time increase the levels of photosensitizer (PplX) within the cells, thus enhancing responsiveness to therapy. The project is translational in nature, with clinical and basic science components.
Aim 1 is preclinical, and uses mouse models of SCC and BCC to determine optimal dosing regimens for the systemic differentiating agent.
Aims 2 and 3 are clinical studies to determine the efficacy of topical Vit D and oral MTXas combination agents with ALA-PDT.
These Aims will also test new in vivo multimodal subsurface imaging devices for PplX detection, and evaluate C/EBP transcription factors ex vivo as prognostic markers of tumor response.
Aim 4 consists of mechanistic experiments that will examine regulatory functions and the prognostic value of the C/EBPs in terms of PplX accumulation, using the preclinical models and examining tissue-banked skin tumor specimens from the clinical studies.
Aim 4 is significant because those experiments will contribute to further improvements in the treatment design. The project involves significant collaborations with Project 4, Core B, and Core C of the Program. In summary, the potentialbenefits to public health will be the development of new rational combination approaches for PDT of skin cancer that include the manipulation of tumor cell physiology to increase endogenous levels of PplX. This will be coupled with individualized treatment planning based upon advanced PplX dosimetry and measurement of differentiation-responsive molecular markers, to optimize treatment response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA084203-10
Application #
8403908
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
10
Fiscal Year
2013
Total Cost
$249,807
Indirect Cost
$44,671
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Huang, Huang-Chiao; Mallidi, Srivalleesha; Liu, Joyce et al. (2016) Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer Res 76:1066-77
Tangutoori, Shifalika; Spring, Bryan Q; Mai, Zhiming et al. (2016) Simultaneous delivery of cytotoxic and biologic therapeutics using nanophotoactivatable liposomes enhances treatment efficacy in a mouse model of pancreatic cancer. Nanomedicine 12:223-34
Obaid, Girgis; Broekgaarden, Mans; Bulin, Anne-Laure et al. (2016) Photonanomedicine: a convergence of photodynamic therapy and nanotechnology. Nanoscale 8:12471-503
Pogue, Brian W; Paulsen, Keith D; Samkoe, Kimberley S et al. (2016) Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention. Med Phys 43:3143
Pogue, Brian W; Elliott, Jonathan T; Kanick, Stephen C et al. (2016) Revisiting photodynamic therapy dosimetry: reductionist & surrogate approaches to facilitate clinical success. Phys Med Biol 61:R57-89
Huggett, Matthew T; Tudzarova, Slavica; Proctor, Ian et al. (2016) Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Oncotarget 7:18495-507
Spring, Bryan Q; Bryan Sears, R; Zheng, Lei Zak et al. (2016) A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat Nanotechnol 11:378-87
de Souza, Ana Luiza Ribeiro; Marra, Kayla; Gunn, Jason et al. (2016) Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer. Br J Cancer 115:805-13
Mohammad, Goran Hamid; Olde Damink, S W M; Malago, Massimo et al. (2016) Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome. PLoS One 11:e0151635
Mallidi, Srivalleesha; Mai, Zhiming; Rizvi, Imran et al. (2015) In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints. J Biomed Opt 20:048003

Showing the most recent 10 out of 150 publications